P. Schoeffski - University Hospitals Leuven, University of Torino

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 23 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

673P A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours

P. Schoeffski,P. Lorusso,N. Yamamoto,I. Lugowska,V. Moreno Garcia, U. Lauer, C. Hu,G. Jayadeva, M. Lahmar,M. Gounder

Annals of Oncology (2023): S472-S473

引用0浏览0引用

A phase I/Ib study evaluating the safety and tolerability of NIZ985 alone and in combination with spartalizumab (anti ePD-1) in patients (pts) with solid tumors or lymphoma

E. Garralda,A. Oberoi, T. Koyama,P. Schoeffski,P. A. Ascierto, C-C. Lin,M. H. H. Schuler, Y. Xing,S. P. Patel,V. Subbiah, N. Lewis, J. B. Lee, N. B. Hassounah, L. H. Lee, M. Roy, S. Banerjee, A. Reynolds, L. Wang Lakshman, T. Shimizu

ANNALS OF ONCOLOGY (2023): S484-S484

引用0浏览0引用

695P A Phase I/Ib Study Evaluating the Safety and Tolerability of NIZ985 Alone and in Combination with Spartalizumab (Anti–pd-1) in Patients (pts) with Solid Tumors or Lymphoma

E. Garralda,A. Oberoi,T. Koyama,P. Schoeffski,P.A. Ascierto,C-C. Lin,M.H.H. Schuler, Y. Xing,S.P. Patel,V. Subbiah, N. Lewis, J.B. Lee, N.B. Hassounah, L.H. Lee, M. Roy,S. Banerjee, A. Reynolds, L. Wang Lakshman,T. Shimizu

Annals of Oncology (2023): S484

引用0浏览0引用

1944P MAGE-A4 and NY-ESO-1 Expression Analysed in a Synovial Sarcoma Tissue Micro-Array

L. De Cock,A. Wozniak,U. Vanleeuw, K. Wyns, C-J. Lee,R. Sciot,P. Schoeffski

Annals of Oncology (2023): S1043

引用0浏览0引用

42O A Phase Ia/b, Dose-Escalation and Expansion Study Evaluating the MDM2–p53 Antagonist BI 907828 in Patients with Solid Tumours: Safety and Efficacy in Patients with Dedifferentiated Liposarcoma (DDLPS)

P. Schoeffski, N. Yamamoto, T. Bauer, M. Patel,P. Lorusso, M. Lahmar, S. Durland-Busbice,J. Geng,M. Gounder

ESMO Openno. 1 (2023): 101079-101079

引用0浏览0引用

1514P Anti-tumor Effects of the Novel KIT Mutant Inhibitor M4205 in Gastrointestinal Stromal Tumor (GIST) Xenograft Models

L. De Sutter,A. Wozniak, J. Verreet,U. Vanleeuw,L. De Cock, N. Linde, C. Drechsler, C. Esdar,R. Sciot,P. Schoeffski

ANNALS OF ONCOLOGYno. 7 (2022): S1239-S1239

引用0浏览0引用

452O A Phase I Dose-Escalation and Expansion Study Evaluating the Safety and Efficacy of the MDM2–p53 Antagonist BI 907828 in Patients (pts) with Solid Tumours

P. Schoeffski, N. Yamamoto, T. Bauer,M. Patel,M. M. Gounder,J. Geng, R. Sailer,G. Jayadeva,P. Lorusso

Annals of Oncology（2022）

引用1浏览0引用

1919P Nintedanib (BIBF1120) after First Line Therapy in Progressive Medullary Thyroid Cancer: A Multicenter EORTC Prospective Randomized Double-Blind Phase II Study (NCT01788982)

K. Newbold,P. Schoeffski,B. Hasan,L. D. Locati,Y. Godbert,C. de la Fouchardiere,L. Bastholt,M. Fassnacht, N. Reed,Y. Lalami,C. Chougnet,C. Schvartz,E. Kapiteijn,M. J. Schlumberger, W. Sents,N. Sauve,S. Leboulleux

Annals of oncology（2020）

引用1浏览0引用

Quality of Life (qol) and Self-Reported Function with Ripretinib in ≥4Th-Line Therapy for Patients with Gastrointestinal Stromal Tumors (GIST): Analyses from INVICTUS

S. Bauer,M. C. Heinrich,S. George,J. R. Zalcberg,H. Gelderblom,P. Schoeffski,C. Serrano, R. L. Jones,S. Attia,G. D'amato,P. Chi,P. Reichardt, C. C. Becker,J. Meade,R. Ruiz-Soto,M. von Mehren,J. -Y. Blay

Journal of Clinical Oncology（2020）

引用7浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn